Cagrilintide (5mg)

Cagrilintide is a long-acting amylin analog — a synthetic version of a natural pancreatic hormone called amylin, engineered to last much longer in the body. Amylin is co-released with insulin after eating and contributes to feelings of fullness, slows how quickly your stomach empties, and helps control post-meal blood sugar. Native amylin is broken down within minutes, which is why Cagrilintide was engineered — a stable, once-weekly form that allows the same biological effects to be studied over longer time courses.

Semaglutide and Tirzepatide work through the incretin pathway — GLP-1 (and GIP, in Tirzepatide's case). Cagrilintide works through a completely separate pathway: amylin. That's the key distinction. Where GLP-1 and GIP agonists reduce appetite and improve glucose control through one mechanism, Cagrilintide adds an entirely different satiety signal on top. This is why the combination of Cagrilintide + Semaglutide (CagriSema) is being studied so intensely — it stacks two independent appetite-control mechanisms rather than amplifying one.

CagriSema is the combination of Cagrilintide and Semaglutide — currently one of the most-watched compound combinations in Phase 3 weight management research. Cagrilintide contributes an amylin-pathway satiety signal; Semaglutide contributes the GLP-1 incretin signal. Together, they produce additive appetite suppression that early trial data suggests rivals the highest-performing tri-agonist compounds. Researchers studying combination weight-management protocols are increasingly looking at CagriSema as the next-generation dual-mechanism approach.

Cagrilintide monotherapy has shown meaningful weight reduction in clinical research — meaningful, but smaller than what GLP-1 agonists deliver alone. Its real research interest is as a combination compound. When Cagrilintide is studied alongside Semaglutide (the CagriSema combination), trial data has shown body weight reductions that approach the strongest figures recorded in clinical weight management literature — making it one of the most active areas of current metabolic research.

Cagrilintide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized Cagrilintide vials at -20°C, away from light and moisture. After reconstitution with BAC water, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze the reconstituted solution.

Cagrilintide (5mg) will be available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia, reducing delays linked to international freight and customs processing. Batch-specific Certificate of Analysis access will be available in our CoA library.

Cagrilintide (5mg) is currently available on pre-order at Aussie Peptides, with dispatch expected between 16 September 2026 and 18 September 2026. Cagrilintide (5mg) is priced at $109.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.

Once restocked, ordering is straightforward — add Cagrilintide (5mg) to your cart on the Aussie Peptides website and complete checkout through our secure payment system. All orders are fulfilled domestically and shipped with tracking to any address across Australia.